Genentech and Wyeth in manufacturing agreement
US biotech giant Genentech and Wyeth Pharmaceuticals, a division of Wyeth have entered into a manufacturing agreement for Herceptin (trastuzumab).
US biotech giant Genentech and Wyeth Pharmaceuticals, a division of Wyeth have entered into a manufacturing agreement for Herceptin (trastuzumab).
Under this agreement, Wyeth Pharmaceuticals will manufacture Herceptin bulk drug substance for Genentech at Wyeth's production facility in Andover, Massachusetts. Financial terms of the agreement have not been disclosed.
'Wyeth has a strong track record as a manufacturer of biopharmaceuticals, and we are very pleased to enter into this agreement for the production of Herceptin, which will assist us in our mission of delivering life-saving therapies to patients,' said David Ebersman, senior vice president, product operations, Genentech. 'The additional capacity provided by this agreement will help us manufacture product in response to increases in demand for our therapeutic antibody products.'
'This agreement provides Wyeth with an important opportunity to continue to build our biopharmaceutical business by working with Genentech, which is one of the industry's leaders in biotechnology and oncology innovation,' said Cavan Redmond, executive vice president and general manager, Wyeth BioPharma. 'We are looking forward to using our biotechnology expertise and experience to manufacture this key oncology product in our Andover facility.'